CAMBRIDGE, MA--(Marketwire - July 31, 2012) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report second quarter 2012 financial results after the NASDAQ Global Market closes on Tuesday, August 7, 2012. Subsequently, at 5:00 p.m., Eastern Time (2:00 p.m., Pacific time), Chris Garabedian, Sarepta’s President and CEO, will host a conference call to discuss second quarter financial results and to provide a corporate update.
The conference call may be accessed by dialing 800.446.2782 for domestic and international callers. The passcode for the call is 33002736. Please specify to the operator that you would like to join the “Sarepta second quarter 2012 earnings call.” The conference call will be webcast live under the events section of Sarepta’s website at www.sareptatherapeutics.com and will be archived there following the call for 90 days. Please connect to Sarepta’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world’s most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com.
Sarepta Investor and Media Contact:
Erin Cox
425.354.5140
Email Contact
